Applications for Social and
Clinical Innovation
RMP3D Technology:
Project for the application of RMP3D technology (UAB - Barcelona) for social and economic impact in Europe.
Barcelona, Spain - Fev / May 2020
User Research | Social Innovation | Business Model
The project was developed as part of the Technology for Social Innovation (TeSI) program, focusing on identifying commercial applications for the RMP3D technology, created by the Computer Vision Center (UAB), led by researcher Alicia Fornés.
RMP3D, supported by the European Union's Horizon 2030 program, combines hardware and advanced algorithms to capture and interpret 3D movements, generating insights into the neuromuscular system.
The main objective was to explore solutions that maximized social and economic impact, connecting advanced technology to value creation in the European context.
The Project
This project involved the use of Design Thinking, Data Engineering, and Market Strategy to explore the technology's application possibilities in real-world scenarios. The process followed four main stages: discover, define, develop, and deliver, enabling continuous iterations and alignment between technical feasibility, human needs, and economic impact.
Challenges explored
How can the RMP3D technology:
Solve social challenges through innovation?
Improve patient experience and reduce costs in clinical trials?
Transform movement data into objective metrics for faster and more accurate decisions?
Research and Dicovery
The initial research, based on scientific literature, expert interviews, and trend mapping, resulted in three main applications:
Migraine attack prediction: Enabling preventive interventions.
Remote monitoring of patients with multiple sclerosis: Facilitating medication adjustments.
Clinical outcomes measurement tool for drug trials: Reducing costs and increasing efficiency.
The solution focused on multiple sclerosis was selected as the most promising, due to its high potential for economic and social impact, as well as addressing a critical issue for the pharmaceutical industry
Research processes used
Key insights
RMP3D transforms clinical monitoring by replacing sporadic assessments with continuous and precise metrics, captured through wearable devices. With advanced sensors and proprietary algorithms, it translates 3D movements into objective data to assess the neuromuscular system.
Benefits
Cost reduction: Reduces time and sample size in clinical trials, cutting R&D costs and making treatments more accessible for patients and healthcare systems.
Enhanced experience: Monitoring from the comfort of home, eliminating the need for travel.
Patient-centered innovation: Granular, continuous data provides greater accuracy and personalization in treatment monitoring, fostering a more humanized and effective approach.
Lower dropout rates: Convenience reduces attrition in clinical trials.
Data acquisition processes
Impact on the Market
The market analysis identified that RMP3D can reach between 2,000 and 10,000 patients within five years, depending on the adoption scenario. This approach is centered around a Service Design model, where the patient experience is the priority, combined with operational efficiency for pharmaceutical companies.
Key elements of the developed service:
Integration Engineering: Wearable devices that capture data continuously and discreetly.
User Journey: Mapping critical touchpoints to ensure a smooth and easily adoptable service.
Value Ecosystem: Alignment between stakeholders.
Conclusion
The RMP3D technology stands out for its potential to transform the clinical trial landscape, with a patient-centered approach, backed by data, and designed to scale in the European market. By reducing sample sizes and the duration of trials, RMP3D enables significant cost reductions in drug development, especially for multiple sclerosis, benefiting patients, healthcare systems, and the pharmaceutical industry. By replacing time-consuming in-person testing with continuous monitoring, the technology also improves the quality of life for the 40,000 patients involved in clinical trials, while promoting cost savings for the sector.